Speckle-type POZ protein negatively regulating the metastasis of HepG2 cells in vitro

LIANG Shao-hua WANG Zhi-qiang JI Pi-you*

doi:10.16098/j.issn.0529-1356.2019.03.007

PDF(7939 KB)

Acta Anatomica Sinica ›› 2019, Vol. 50 ›› Issue (3) : 304-309. DOI: 10.16098/j.issn.0529-1356.2019.03.007

Cell and Molecules Biology

Speckle-type POZ protein negatively regulating the metastasis of HepG2 cells in vitro

LIANG Shao-hua WANG Zhi-qiang JI Pi-you*

Author information +

History +

Abstract

Objective To explore the effect of speckle type POZ protein (SPOP) on migration and invasion of HepG2 cells in vitro. Methods Stable gain- and loss- of SPOP expression HepG2 cell lines were constructed using plasmid overexpression and shRNA technique. Western blotting was used to detect the overexpression and knockdown effect of SPOP, and the effects of SPOP on the migration and invasion of HepG2 cells was examined by Transwell assays and wound-healing assay was also used to detect HepG2 cells’ migration in vitro. Results The effect of gain- and loss- of SPOP expression was obvious in constructed stable HepG2 cells. HepG2 cells’migration and invasion were significantly decreased by gain-SPOP expression, while the cells’migration and invasion were obviously enhanced in loss-SPOP expression HepG2 cells. Wound-healing assay exhibited that SPOP overexpression suppressed HepG2 cells’ migration and that downregulation of SPOP promoted the migration of HepG2 cells. Conclusion SPOP could negatively regulate HepG2 cells’ metastasis in vitro.

Key words

SPeckle-type POZ protein / HepG2 cell / Metastasis / Western blotting / Wound healing assay

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIANG Shao-hua WANG Zhi-qiang JI Pi-you. Speckle-type POZ protein negatively regulating the metastasis of HepG2 cells in vitro[J]. Acta Anatomica Sinica. 2019, 50(3): 304-309 https://doi.org/10.16098/j.issn.0529-1356.2019.03.007

References

［1］ Ascoli CA,Maul GG. Identification of a novel nuclear domain［J］. J Cell Biol, 1991,112(5):785-795.
［2］ Andrade LE, Chan EK, Raska Ⅰ, et al. Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80coilin［J］. J Exp Med, 1991,173(6):1407-1419.
［3］ Li C, Ao J, Fu J, et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1［J］. Oncogene, 2011,30(42):4350-4364.
［4］ An J, Wang C, Deng Y, et al. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants［J］. Cell Rep, 2014,6(4):657-669.
［5］ Zhang L, Peng S, Dai X, et al. Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells［J］. Cancer Lett, 2017,390:11-20.
［6］ Hu X, Yang Z, Zeng M, et al. Speckle-type POZ (pox virus and zinc finger protein) protein gene deletion in ovarian cancer: fluorescence in situ hybridization analysis of a tissue microarray［J］. Oncol Lett, 2016,12(1):658-662.
［7］ Zeng C, Wang Y, Lu Q, et al. SPOP suppresses tumorigenesis by regulating Hedgehog/Gli2 signaling pathway in gastric cancer［J］. J Exp Clin Cancer Rese, 2014,33:75.
［8］ Gao K, Jin X, Tang Y, et al. Tumor suppressor SPOP mediates the proteasomal degradation of progesterone receptors (PRs) in breast cancer cells［J］. Am J Cancer Res, 2015,5(10):3210-3220.
［9］ El-Serag HB,Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis［J］. Gastroenterology, 2007,132(7):2557-2576.
［10］ Lau WY,Lai EC. Hepatocellular carcinoma: current management and recent advances［J］. Hepatobiliary Pancreat Dis Int, 2008,7(3):237-257.
［11］ Dahmani R, Just PA,Perret C. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma［J］. Clin Res Hepatol Gastroenterol, 2011,35(11):709-713.
［12］ Komposch K,Sibilia M. EGFR signaling in liver diseases［J］. Int J Mol Sci, 2015,17(1):pii E30.
［13］ Sia D, Alsinet C, Newell P, et al. VEGF signaling in cancer treatment［J］. Curr Pharm Des, 2014,20(17):2834-2842.
［14］ Li G, Ci W, Karmakar S, et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer［J］. Cancer Cell, 2014,25(4):455-468.
［15］ Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer［J］. Nat Genet, 2012,44(6):685-689. ［16］ Ding D, Song T, Jun W, et al. Decreased expression of the SPOP gene is associated with poor prognosis in glioma［J］. Int J Oncol, 2015,46(1):333-341.
［17］ Luo J, Bao YC, Ji XX, et al. SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth［J］. Biochem Biophys Res Commun, 2017,483(2):880-884.
［18］ Liu ChJ, Zhang XY, Shan ZhY, et al. Establishment of a tumor-bear mouse model carrying human HepG2 cells and exploration of immune tolerance［J］. Acta Anatomica Sinica, 2015, 46(4): 509-513. (in Chinese)
刘春佳, 张星宇, 单智焱, 等. 人肝癌HepG2细胞小鼠荷瘤模型的建立及免疫耐受的探讨［J］. 解剖学报, 2015,46(4):509-513.